These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 31829087)

  • 1. The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis.
    Lei Y; Zhang X; Lin H; Feng Y; Wang J; Luo R
    Mod Rheumatol; 2021 Jan; 31(1):151-161. PubMed ID: 31829087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis.
    Bearzi P; Navarini L; Currado D; Marino A; Minerba M; Salvolini C; Perrone A; Frascà L; Liakouli V; Vomero M; Berardicurti O; Giacomelli R
    Clin Exp Rheumatol; 2024 Aug; 42(8):1615-1622. PubMed ID: 38819960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review.
    Johnson SR; Brode SK; Mielniczuk LM; Granton JT
    Respir Med; 2012 May; 106(5):730-9. PubMed ID: 22366298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP;
    J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
    Maki H; Kubota K; Hatano M; Minatsuki S; Amiya E; Yoshizaki A; Asano Y; Morita H; Sato S; Komuro I
    Int Heart J; 2020; 61(2):413-418. PubMed ID: 32224603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 10. Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis.
    Theodorakopoulou MP; Minopoulou I; Sarafidis P; Kamperidis V; Papadopoulos C; Dimitroulas T; Boutou AK
    Rheumatol Int; 2021 Jun; 41(6):1045-1053. PubMed ID: 33830321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes.
    Brown Z; Proudman S; Morrisroe K; Stevens W; Hansen D; Nikpour M
    Semin Arthritis Rheum; 2021 Jun; 51(3):495-512. PubMed ID: 33857705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
    Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
    Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Kuang HY; Li Q; Du HA; Chen M; Yin YH
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study.
    Xanthouli P; Uesbeck P; Lorenz HM; Blank N; Eichstaedt CA; Harutyunova S; Egenlauf B; Coghlan JG; Denton CP; Grünig E; Benjamin N
    Arthritis Res Ther; 2024 Jul; 26(1):136. PubMed ID: 39026360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
    Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
    Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Colunga-Argüelles D; Argibay A; Marí-Alfonso B; Marín-Ballvé A; Pla-Salas X; Chamorro AJ; Castro-Salomó A; Madroñero-Vuelta AB; Sánchez-García ME; Sáez-Comet L; González-Echávarri C; Ortego-Centeno N; Vargas-Hitos JA; Todolí-Parra JA; Trapiella-Martínez L; Lledó GM; Freire M; Fonollosa-Pla V; Simeón-Aznar CP;
    Rheumatology (Oxford); 2021 Feb; 60(2):872-880. PubMed ID: 32844220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.